• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病中的非编码 RNA:潜在的诊断和预后生物标志物。

Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers.

机构信息

Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.

College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Education City, Doha, Qatar.

出版信息

Dis Markers. 2020 Aug 27;2020:8822859. doi: 10.1155/2020/8822859. eCollection 2020.

DOI:10.1155/2020/8822859
PMID:33133304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7593715/
Abstract

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide in part due to the concomitant obesity pandemic and insulin resistance (IR). It is increasingly becoming evident that NAFLD is a disease affecting numerous extrahepatic vital organs and regulatory pathways. The molecular mechanisms underlying the nonalcoholic steatosis formation are poorly understood, and little information is available on the pathways that are responsible for the progressive hepatocellular damage that follows lipid accumulation. Recently, much research has focused on the identification of the epigenetic modifications that contribute to NAFLD pathogenesis. Noncoding RNAs (ncRNAs) are one of such epigenetic factors that could be implicated in the NAFLD development and progression. In this review, we summarize the current knowledge of the genetic and epigenetic factors potentially underlying the disease. Particular emphasis will be put on the contribution of microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) to the pathophysiology of NAFLD as well as their potential use as therapeutic targets or as markers for the prediction and the progression of the disease.

摘要

非酒精性脂肪性肝病(NAFLD)是目前全球最常见的慢性肝病,部分原因是肥胖症和胰岛素抵抗(IR)的同时流行。越来越明显的是,NAFLD 是一种影响众多肝外重要器官和调节途径的疾病。非酒精性脂肪性形成的分子机制尚未完全了解,对于导致脂质积累后肝细胞损伤进展的途径知之甚少。最近,大量研究集中在确定导致 NAFLD 发病机制的表观遗传修饰上。非编码 RNA(ncRNA)是一种可能与 NAFLD 发展和进展有关的表观遗传因素。在这篇综述中,我们总结了潜在疾病的遗传和表观遗传因素的最新知识。特别强调微小 RNA(miRNA)、长非编码 RNA(lncRNA)和环状 RNA(circRNA)对 NAFLD 病理生理学的贡献,以及它们作为治疗靶点或作为疾病预测和进展的标志物的潜在用途。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1d/7593715/6b1ac13e5a74/DM2020-8822859.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1d/7593715/f817a97fa57f/DM2020-8822859.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1d/7593715/428acdae9c00/DM2020-8822859.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1d/7593715/6b1ac13e5a74/DM2020-8822859.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1d/7593715/f817a97fa57f/DM2020-8822859.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1d/7593715/428acdae9c00/DM2020-8822859.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce1d/7593715/6b1ac13e5a74/DM2020-8822859.003.jpg

相似文献

1
Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers.非酒精性脂肪性肝病中的非编码 RNA:潜在的诊断和预后生物标志物。
Dis Markers. 2020 Aug 27;2020:8822859. doi: 10.1155/2020/8822859. eCollection 2020.
2
Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease.非编码 RNA 作为非酒精性脂肪性肝病中表观遗传调控的附加介质。
World J Gastroenterol. 2022 Sep 21;28(35):5111-5128. doi: 10.3748/wjg.v28.i35.5111.
3
The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC.非编码RNA在非酒精性脂肪性肝病(NAFLD)相关肝细胞癌(HCC)的发生发展及演变过程中的意义
Int J Mol Sci. 2022 Oct 15;23(20):12370. doi: 10.3390/ijms232012370.
4
Role of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease.非编码RNA在非酒精性脂肪性肝病发生发展中的作用
Biomed Res Int. 2019 Feb 26;2019:8690592. doi: 10.1155/2019/8690592. eCollection 2019.
5
The impact and role of identified long noncoding RNAs in nonalcoholic fatty liver disease: A narrative review.鉴定长非编码 RNA 在非酒精性脂肪性肝病中的作用和影响:叙述性综述。
J Clin Lab Anal. 2023 Jun;37(11-12):e24943. doi: 10.1002/jcla.24943. Epub 2023 Jul 12.
6
Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review.解析表观遗传修饰在脂肪性肝病中的作用:系统评价。
Eur J Clin Invest. 2021 May;51(5):e13479. doi: 10.1111/eci.13479. Epub 2021 Jan 4.
7
Long noncoding RNAs in nonalcoholic fatty liver disease and liver fibrosis: state-of-the-art and perspectives in diagnosis and treatment.长链非编码 RNA 与非酒精性脂肪性肝病和肝纤维化:诊断与治疗的最新技术和展望。
Drug Discov Today. 2020 Jul;25(7):1277-1286. doi: 10.1016/j.drudis.2020.05.009. Epub 2020 May 19.
8
MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease.微小RNA作为非酒精性脂肪性肝病的生物标志物和调节因子
J Dig Dis. 2016 Nov;17(11):708-715. doi: 10.1111/1751-2980.12408.
9
Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease.瘦型非酒精性脂肪性肝病中的表观遗传调控。
Int J Mol Sci. 2023 Aug 16;24(16):12864. doi: 10.3390/ijms241612864.
10
Long non-coding RNA in Non-alcoholic fatty liver disease.长链非编码 RNA 与非酒精性脂肪性肝病。
Adv Clin Chem. 2022;110:1-35. doi: 10.1016/bs.acc.2022.06.001. Epub 2022 Aug 31.

引用本文的文献

1
The use of circulating miRNAs for the diagnosis, prognosis, and personalized treatment of MASLD.循环微小RNA在非酒精性脂肪性肝病的诊断、预后及个性化治疗中的应用
J Physiol Biochem. 2025 Jul 16. doi: 10.1007/s13105-025-01110-w.
2
Exploring the Putative Involvement of MALAT1 in Mediating the Beneficial Effect of Exendin-4 on Oleic Acid-Induced Lipid Accumulation in HepG2 Cells.探索MALAT1在介导艾塞那肽-4对油酸诱导的HepG2细胞脂质积累的有益作用中的潜在作用。
Biomedicines. 2025 Feb 5;13(2):370. doi: 10.3390/biomedicines13020370.
3
Multidimensional landscape of non-alcoholic fatty liver disease-related disease spectrum uncovered by big omics data: Profiling evidence and new perspectives.

本文引用的文献

1
LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma.长链非编码 RNA 在慢性肝脏疾病与肝细胞癌之间发挥关联作用。
Int J Mol Sci. 2020 Apr 20;21(8):2883. doi: 10.3390/ijms21082883.
2
The Roles and Mechanisms of lncRNAs in Liver Fibrosis.长链非编码 RNA 在肝纤维化中的作用与机制。
Int J Mol Sci. 2020 Feb 21;21(4):1482. doi: 10.3390/ijms21041482.
3
Research progress on the interactions between long non-coding RNAs and microRNAs in human cancer.长链非编码RNA与微小RNA在人类癌症中的相互作用研究进展
大组学数据揭示的非酒精性脂肪性肝病相关疾病谱的多维图景:剖析证据与新视角
Smart Med. 2023 Apr 17;2(2):e20220029. doi: 10.1002/SMMD.20220029. eCollection 2023 May.
4
Serum miR‑29 is increased in mice with early liver fibrosis.早期肝纤维化小鼠血清中的miR-29水平升高。
Exp Ther Med. 2024 May 15;28(1):285. doi: 10.3892/etm.2024.12573. eCollection 2024 Jul.
5
Competitive adsorption of microRNA-532-3p by circular RNA SOD2 activates Thioredoxin Interacting Protein/NLR family pyrin domain containing 3 pathway and promotes pyroptosis of non-alcoholic fatty hepatocytes.环状RNA SOD2对微小RNA-532-3p的竞争性吸附激活硫氧还蛋白相互作用蛋白/含NLR家族pyrin结构域蛋白3通路并促进非酒精性脂肪性肝细胞焦亡
Eur J Med Res. 2024 Apr 24;29(1):250. doi: 10.1186/s40001-024-01817-4.
6
Circular RNAs, Noncoding RNAs, and N6-methyladenosine Involved in the Development of MAFLD.参与MAFLD发生发展的环状RNA、非编码RNA和N6-甲基腺苷
Noncoding RNA. 2024 Feb 5;10(1):11. doi: 10.3390/ncrna10010011.
7
Targeted MicroRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several MicroRNAs to Reduce Steatosis in HepG2 Cells.靶向 microRNA 谱分析显示,Exendin-4 通过调节几种 microRNAs 的表达来减少 HepG2 细胞中的脂肪变性。
Int J Mol Sci. 2023 Jul 18;24(14):11606. doi: 10.3390/ijms241411606.
8
Diagnostic potential and pathogenic performance of circulating miR-146b, miR-194, and miR-214 in liver fibrosis.循环miR-146b、miR-194和miR-214在肝纤维化中的诊断潜力及致病作用
Noncoding RNA Res. 2023 Jun 26;8(4):471-480. doi: 10.1016/j.ncrna.2023.06.004. eCollection 2023 Dec.
9
Could Long Non-Coding RNA MEG3 and PTENP1 Interact with miR-21 in the Pathogenesis of Non-Alcoholic Fatty Liver Disease?长链非编码RNA MEG3和PTENP1在非酒精性脂肪性肝病发病机制中是否与miR-21相互作用?
Biomedicines. 2023 Feb 15;11(2):574. doi: 10.3390/biomedicines11020574.
10
Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies.非酒精性脂肪性肝炎-肝细胞癌涉及的流行病学、遗传学、致病性、代谢、表观遗传学方面:当前治疗策略
Cancers (Basel). 2022 Dec 20;15(1):23. doi: 10.3390/cancers15010023.
Oncol Lett. 2020 Jan;19(1):595-605. doi: 10.3892/ol.2019.11182. Epub 2019 Dec 4.
4
Circular RNAs: Biogenesis, Mechanism, and Function in Human Cancers.环状 RNA:在人类癌症中的生物发生、机制和功能。
Int J Mol Sci. 2019 Aug 13;20(16):3926. doi: 10.3390/ijms20163926.
5
Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).非酒精性脂肪性肝病 (NAFLD) 和非酒精性脂肪性肝炎 (NASH) 的检测现状。
Cells. 2019 Aug 7;8(8):845. doi: 10.3390/cells8080845.
6
Circulating MicroRNAs in Cancer: Potential and Challenge.癌症中的循环微小RNA:潜力与挑战
Front Genet. 2019 Jul 18;10:626. doi: 10.3389/fgene.2019.00626. eCollection 2019.
7
Non-Alcoholic Fatty Liver Disease, an Overview.非酒精性脂肪性肝病概述
Integr Med (Encinitas). 2019 Apr;18(2):42-49.
8
GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network.全基因组关联研究和非酒精性脂肪性肝病的富集分析在 eMERGE 网络中确定了新的与疾病相关的基因和途径。
BMC Med. 2019 Jul 17;17(1):135. doi: 10.1186/s12916-019-1364-z.
9
Special Issue: MicroRNA Regulation in Health and Disease.特刊:微小 RNA 在健康和疾病中的调控作用。
Genes (Basel). 2019 Jun 15;10(6):457. doi: 10.3390/genes10060457.
10
Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的调控性非编码RNA网络
Front Physiol. 2019 Mar 19;10:279. doi: 10.3389/fphys.2019.00279. eCollection 2019.